Research Article

Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases

Table 2

Basal characteristics of patients with metastatic breast cancer.

Parameter Total
(%)
Metastatic site value
Bone
(%)
Brain
(%)
Liver
(%)
Lung
(%)

Age (years)
 ≤5065 (51.6)17 (54.8)17 (47.2)4 (36.4)27 (56.3)0.605
 >5061 (48.4)14 (45.2)19 (52.8)7 (63.6)21 (43.8)
ER
 Negative59 (46.8)6 (19.4)25 (69.4)2 (18.2)26 (54.2)<0.001
 Positive67 (53.2)25 (80.6)11 (30.6)9 (81.8)22 (45.8)
PR
 Negative86 (68.3)16 (51.6)35 (97.2)3 (27.3)32 (66.7)<0.001
 Positive40 (31.7)15 (48.4)1 (2.8)8 (72.7)16 (33.3)
HER-2
 Negative86 (68.3)25 (80.6)18 (50.0)9 (81.8)34 (70.8)0.032
 Positive40 (31.7)6 (19.4)18 (50.0)2 (18.2)14 (29.2)
Ki-67 LI
 <1484 (66.7)27 (87.1)18 (50.0)9 (81.8)30 (62.5)0.008
 ≥1442 (33.3)4 (12.9)18 (50.0)2 (18.2)18 (37.5)
Molecular subtype
 Luminal A44 (34.9)21 (67.7)3 (8.3)6 (54.5)14 (29.2)<0.001
 Luminal B24 (19.0)5 (16.1)8 (22.2)3 (27.3)8 (16.7)
 HER-225 (19.8)3 (9.7)12 (33.3)1 (9.1)9 (18.8)
 TNBC33 (26.2)2 (6.5)13 (36.1)1 (9.1)17 (35.4)
Patient death41 (32.5)16 (51.6)11 (30.6)4 (36.4)10 (20.8)0.041

ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor-2; LI, labeling index; TNBC, triple negative breast cancer.